Search
Ulcerative Colitis Paid Clinical Trials in New Jersey
A listing of 10 Ulcerative Colitis clinical trials in New Jersey actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 10 of 10
The state of New Jersey currently has 10 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
Featured Trial
Ulcerative colitis (UC) Trials
Recruiting
Ulcerative colitis (UC) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Ulcerative colitis (UC)
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Ulcerative Colitis Study For Adolescents
Recruiting
We are looking for children 2 to 17 years old diagnosed with ulcerative colitis to join our latest study to help us further develop our knowledge of UC and discover potential new medication options for those whose previous treatment has not been successful.
Conditions:
Ulcerative Colitis
Ulcerative Colitis (UC)
Ulcerative Colitis Chronic Moderate
Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Featured Trial
Ulcerative Colitis Clinical Trial
Recruiting
Are you or someone you know struggling with Ulcerative Colitis? A clinical study in the area is currently open to enroll participants. Eligible adults will receive study-related medical care at no cost. Health insurance is not required.
Conditions:
Ulcerative Colitis
Ulcerative Colitis (UC)
Active Ulcerative Colitis
Moderate to Severe Ulcerative Colitis
Ulcerative Colitis Chronic Mild
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).
Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/19/2024
Locations: Sanmora Bespoke Clinical Research Solutions, East Orange, New Jersey +4 locations
Conditions: Ulcerative Colitis
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Recruiting
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/17/2024
Locations: Morristown Medical Center, Morristown, New Jersey
Conditions: Ulcerative Colitis
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled.
All eligible participants will initially receive open label tofacitinib... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/05/2024
Locations: Atlantic Children's Health-Pediatric Gastroenterology & Nutrition, Morristown, New Jersey +2 locations
Conditions: Ulcerative Colitis
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/16/2024
Locations: AIG Digestive Disease Research, Florham Park, New Jersey
Conditions: Ulcerative Colitis
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
05/16/2024
Locations: AGA Clinical Research Associates, LLC, Egg Harbor Township, New Jersey
Conditions: Ulcerative Colitis
ABTECT - Maintenance
Recruiting
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins,... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
04/23/2024
Locations: AGA Clinical Research Associates, LLC, Egg Harbor Township, New Jersey +1 locations
Conditions: Ulcerative Colitis
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Recruiting
The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
All
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: Goryeb Children's Hospital, Morristown, New Jersey
Conditions: Ulcerative Colitis, Crohn's Disease
Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC)
Recruiting
The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
01/08/2024
Locations: Allied Health Clinical Research Organization, LLC - Englewood, Englewood, New Jersey +2 locations
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/27/2023
Locations: Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey
1 - 10 of 10